The Ozempic Lawsuit
Ready to Join the Ozempic Lawsuit? Here's What You Need to Know
Recent FDA findings indicate that Ozempic may significantly increase the risk of severe abdominal pain and health issues. If you have been harmed by Ozempic, you could be eligible for compensation.
Ozempic, a common drug for type-2 diabetes and weight loss, is now under scrutiny. The manufacturer, Novo Nordisk, allegedly did not adequately warn users of potential abdominal complications, including gallbladder disease and intestinal blockage.
Our attorneys at Edwards Fingerhut PLLC are the Mass Tort Champs and are ready to help you seek justice and financial relief.
Please reach out to us today to see if you qualify for compensation.
Ozempic Lawsuit Updates
April 2024: Novo Nordisk is actively litigating against pharmacies that distribute unapproved compounded versions of semaglutide, which includes Ozempic, Wegovy, and Rybelsus. The FDA has expressed concerns and advised against compounding these medications, citing violations of federal law.
March 2024: The class action lawsuit’s momentum is increasing, with the first status conference scheduled for March 14, 2024. This meeting will provide early insights into how U.S. District Judge Gene E.K. Pratter will handle this litigation.
February 2024: Recent studies highlight the benefits of GLP-1 receptor agonist medications like Ozempic for diabetes and weight loss but also indicate an increased risk of gastrointestinal issues, such as nausea and vomiting, especially at higher doses. This suggests a need for careful dosing to mitigate adverse effects.
January 2024: The FDA highlighted risks associated with counterfeit versions of Ozempic, particularly compounded forms. Novo Nordisk has reached settlements with several pharmacies selling these non-authentic versions. An ongoing federal lawsuit challenges the safety of Ozempic itself, asserting significant risks not adequately disclosed by the manufacturer.
The FDA is assessing reported cases of hair loss, suicidal thoughts, and aspiration during sedation and anesthesia in individuals using Ozempic. This evaluation is in response to numerous reports logged in the FDA Adverse Event Reporting System database.
December 2023: The European Medicines Agency (EMA) is investigating a potential link between the use of Ozempic and an increased risk of suicidal thoughts and self-harm. This highlights the need for ongoing research and scrutiny.
The federal judge in Louisiana made a significant decision in the lawsuit against Novo Nordisk regarding Ozempic. While claims of breach of express warranty were dismissed, other claims related to inadequate warnings, particularly concerning gastroparesis, were allowed to proceed.
The motion filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML) seeks to centralize all federal gastroparesis lawsuits related to Ozempic, Wegovy, Mounjaro, and similar GLP-1 receptor agonist drugs under the supervision of U.S. District Judge James D. Cain, Jr. in the Western District of Louisiana.
November 2023: Novo Nordisk is facing a class action lawsuit in Canada over allegations that the company failed to provide adequate warnings about the risk of gastroparesis associated with Ozempic.
October 2023: A new study in the Journal of the American Medical Association regarding the potential risks associated with weight loss medications like Ozempic and Wegovy is expected to increase the number of Ozempic lawsuit filings.
September 2023: The FDA revised the label for Ozempic to include possible intestinal blockage in its side effects. The labels for Wegovy and Mounjaro were also updated to note this potential issue.
August 2023: Jaclyn Bjorklund emerged as one of the first individuals to lodge a gastroparesis lawsuit against Ozempic and Mounjaro.
July 2023: ASHP, a leading association of pharmacy specialists, notified Novo Nordisk that due to heightened demand, it was experiencing a shortage of Ozempic and Wegovy.
August 2022: The judiciary consolidated seven lawsuits against Novo Nordisk into a multidistrict litigation (MDL) in Delaware. These suits were against generic pharmaceutical manufacturers for alleged patent violations. This followed a publication in JAMA Internal Medicine linking Ozempic to an increased risk of gallbladder ailments and gallstones.
What is the Ozempic Lawsuit About?
The Ozempic lawsuit is a legal recourse for individuals harmed by the medication. However, not all adverse effects from taking Ozempic qualify for a lawsuit. To file an Ozempic gallbladder lawsuit, you need to meet these requirements:
You used Ozempic before March 2022.
You were later diagnosed with related gallbladder issues.
You received medical treatment for the complications.
Cases involving injuries from using Ozempic for weight loss may have a lesser chance of success, but certain circumstances can provide legal grounds for a lawsuit. These include insufficient warnings from the manufacturer, defective manufacturing or labeling, and unfulfilled safety or efficacy guarantees.
What Can You Receive From Ozempic Lawsuits?
By filing an Ozempic lawsuit, you may be entitled to compensation, including medical expenses, pain and suffering, lost wages, emotional distress, and other damages. Our experienced attorneys will look over your circumstances to figure out the full extent of your potential compensation.
How Can I File an Ozempic Lawsuit?
Filing an Ozempic lawsuit can be daunting, but Edwards Fingerhut PLLC is here to guide you. Our dedicated team has extensive experience handling pharmaceutical injury cases. We will protect your rights and help you through every step of the process.
To get started, contact Edwards Fingerhut for a free consultation. We will evaluate your case, answer your questions, and provide support. We will gather compelling evidence, including medical records and testimony, to construct a robust case. We will also ensure your lawsuit is filed within applicable statutes of limitations.
Throughout the legal process, we will negotiate skillfully to secure a favorable settlement. Our attorneys are prepared to present your case in court if a settlement cannot be reached.
Contact us today to start the claims process.
Understanding the Risks and Side Effects of Ozempic
Ozempic, also known as semaglutide, is an injectable prescription medication approved by the FDA for type 2 diabetes. It belongs to the GLP-1 receptor agonists class, which stimulates insulin production and lowers blood sugar levels. Despite being approved only for diabetes, Ozempic is popular for treating obesity and aiding in weight loss.
Side Effects of Ozempic
While Ozempic effectively manages blood sugar levels, it has potential side effects, including nausea, vomiting, diarrhea, and constipation. More severe complications include gallbladder and pancreas issues, with symptoms like stomach paralysis, gallbladder disease, and even pancreatic cancer.
Gallbladder Problems
Recent research in JAMA Internal Medicine links Ozempic to gallbladder problems. FDA data shows higher rates of gallbladder conditions, including acute gallbladder disease and gallstones, in Ozempic users. The risk is higher with higher doses, longer durations, or use for weight loss.
Pancreatic Cancer
Studies indicate concerns about Ozempic potentially being linked to pancreatitis and pancreatic cancer. These issues highlight the need for patients to stay informed and consider legal action if necessary.
Intestinal Injuries
Recent findings suggest that medications like Ozempic can cause intestinal problems, leading to severe conditions like gastroparesis or stomach paralysis.
Conclusion
If you or a loved one have experienced harm from Ozempic, you don't have to face the consequences alone. At Edwards Fingerhut PLLC, we are here to fight for your rights. Our dedicated team has the knowledge, experience, and determination to pursue justice on your behalf.
